11 December 2015 - NICE has published final draft guidelines now supporting the use of AstraZeneca’s Lynparza on the NHS in England and Wales, marking the first time a cancer drug targeting an inherited genetic fault will be made available on the health service.

For more details, go to: http://www.pharmatimes.com/Article/15-12-11/Landmark_NICE_recommendation_for_AZ_Lynparza.aspx